Aktie A0MXU2 AMAG PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen AMAG Pharmaceuticals, Inc.

Aktien

A0MXU2

US00163U1060

AMAG

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc
AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena
AMAG Pharmaceuticals, Inc. Files Submission in Response to the Food and Drug Administration’s Notice of Opportunity for A Hearing and Proposal to Withdraw Approval of Makena® (Hydroxyprogesterone Caproate Injection)
AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K)
AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K)
AMAG Pharmaceuticals, Inc. Announces Management Changes
AMAG Pharmaceuticals, Inc. Appoints Michael Porter as Chief Executive Officer
AMAG Pharmaceuticals, Inc. Appoints Ozgur Kilic as Chief Financial Officer
AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals
AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 1000
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Composite 1500
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Global BMI Index
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600 Health Care
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P TMI Index
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Index
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value Index
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0MXU2 Aktie
  4. Nachrichten AMAG Pharmaceuticals, Inc.
  5. Andere Sprachen